[en] [en] BACKGROUND: Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare.
OBJECTIVES: To perform a scoping review to identify and catalogue candidate biomarkers of systemic treatment response in psoriasis for the translational research community.
METHODS: A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n ≥ 50) reporting biomarkers associated with systemic treatment response. The main outcomes were any measure of systemic treatment efficacy or safety. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise and mapped to relevant cellular and molecular pathways.
RESULTS: Of 71 included studies (67 studying effectiveness outcomes and eight safety outcomes; four studied both), most reported genomic or proteomic biomarkers associated with response to biologics (48 studies). Methodological or reporting limitations frequently compromised the interpretation of findings, including inadequate control for key covariates, lack of adjustment for multiple testing, and selective outcome reporting. We identified candidate biomarkers of efficacy to tumour necrosis factor inhibitors [variation in CARD14, CDKAL1, IL1B, IL12B and IL17RA loci, and lipopolysaccharide-induced phosphorylation of nuclear factor (NF)-κB in type 2 dendritic cells] and ustekinumab (HLA-C*06:02 and variation in an IL1B locus). None were supported by sufficient evidence for clinical use without further validation studies. Candidate biomarkers were found to be involved in the immune cellular crosstalk implicated in psoriasis pathogenesis, most notably antigen presentation, T helper (Th)17 cell differentiation, positive regulation of NF-κB, and Th17 cell activation.
CONCLUSIONS: This comprehensive catalogue provides a key resource for researchers and reveals a diverse range of biomarker types and outcomes in the included studies. The candidate biomarkers identified require further evaluation in methodologically robust studies to establish potential clinical utility. Future studies should aim to address the common methodological limitations highlighted in this review to expedite discovery and validation of biomarkers for clinical use. What is already known about this topic? Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare. What does this study add? This review provides a comprehensive catalogue of investigated biomarkers of systemic treatment response in psoriasis. A diverse range of biomarker types and outcomes was found in the included studies, serving as a key resource for the translational research community.
Disciplines :
Immunology & infectious disease
Author, co-author :
Corbett, Mark; Centre for Reviews and Dissemination, University of York, York, UK
Ramessur, Ravi ; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Marshall, David; Centre for Reviews and Dissemination, University of York, York, UK
OSTASZEWSKI, Marek ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core
Barbosa, Ines A; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Dand, Nick ; Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Di Meglio, Paola ; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Haddad, Salma; University College Hospital NHS Trust, London, UK
Jensen, Andreas H M ; University of Copenhagen, Copenhagen, Denmark
Koopmann, Witte; Department of Translational Medicine, LEO Pharma A/S, Ballerup, Denmark
Mahil, Satveer K; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Rahmatulla, Seher ; West Hertfordshire NHS Trust, Watford, UK
Rastrick, Joe; Department of Immunology Research, UCB, Brussels, Belgium
Saklatvala, Jake; Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Weidinger, Stephan ; Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
Wright, Kath; Centre for Reviews and Dissemination, University of York, York, UK
Eyerich, Kilian; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany ; Division of Dermatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Barker, Jonathan N; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Ndlovu, Matladi; Department of Immunology Research, UCB, Brussels, Belgium
Conrad, Curdin; Department of Dermatology, Lausanne University Hospital CHUV & University of Lausanne, Lausanne, Switzerland
Skov, Lone ; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Smith, Catherine H; St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
Innovative Medicines Initiative International Psoriasis Council NIHR Biomedical Research Centre (BRC) at King’s College London Innovative Medicines Initiative
Funding text :
This scoping review was supported and funded by the International Psoriasis Council (IPC) and the BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) consortium. This study was also supported by the Psoriasis Association, UK. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 821511 (BIOMAP). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The research also received funding from the National Institute for Health and Care Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. S.K.M. is funded by a Medical Research Council Clinical Academic Research Partnership award (MR/T02383X/1). N.D. is funded by Health Data Research UK (MR/S003126/1).P.D.M. has received research grants from UCB and consultancy or speaker honoraria from Novartis, UCB and Janssen. S.K.M. has received departmental funding from AbbVie, Celgene, Eli Lilly, Janssen‐Cilag, Novartis, Sanofi and UCB. K.E. has received honoraria and/or research grants from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, LEO, Lilly, Novartis, Pfizer and UCB. J.N.B. has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO, Lilly, Novartis, Samsung and Sun Pharma. C.C. has received honoraria and/or research grants from AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung and UCB. L.S. has received honoraria and/or research grants from AbbVie, Almirall, Bristol Myers Squibb, Celgene, Sanofi, UCB, Janssen, LEO Pharma, Lilly and Novartis. C.H.S. reports grants from a Medical Research Council‐funded stratified medicine consortium with multiple industry partners, grants from an Innovative Medicines Initiative (Horizon 2020)‐funded European consortium with multiple industry partners, and others from AbbVie, Novartis, Pfizer, Sanofi, Boehringer Ingelheim and SOBI, outside the submitted work; she is also chair of UK guidelines on biologic therapy in psoriasis. The remaining authors declare that they have no relevant conflicts of interest.
Griffiths CEM, Armstrong AW, Gudjonsson JE et al. Psoriasis. Lancet 2021; 397:1301–15.
Parisi R, Iskandar IYK, Kontopantelis E et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369:m1590.
Warren RB, Gooderham M, Burge R et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol 2020; 82:1138–49.
Puig L. The role of biologics in the treatment of moderate-to-severe plaque psoriasis. G Ital Dermatol Venereol 2017; 152:28–35.
FDA–NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD and Bethesda, MD: U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), 2016.
Aydin B, Arga KY, Karadag AS. Omics-driven biomarkers of psoriasis: recent insights, current challenges, and future prospects. Clin Cosmet Investig Dermatol 2020; 13:611–25.
Broderick C, Christian N, Apfelbacher C et al. The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses. Br J Dermatol 2021; 185:1066–9.
Ramessur R, Corbett M, Marshall D et al. Biomarkers of disease progression in people with psoriasis: a scoping review. Br J Dermatol 2022; 187:481–93. https://doi.org/10.1111/bjd.21627.
Wirsching J, Grassmann S, Eichelmann F et al. Development and reliability assessment of a new quality appraisal tool for cross-sectional studies using biomarker data (BIOCROSS). BMC Med Res Methodol 2018; 18:122.
Hayden JA, van der Windt DA, Cartwright JL et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158:280–6.
Naldi L. Risk factors for psoriasis. Curr Dermatol Rep 2013; 2:58–65.
Ensor JE. Biomarker validation: common data analysis concerns. Oncologist 2014; 19:886–91.
Indhumathi S, Rajappa M, Chandrashekar L et al. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol 2017; 73:965–71.
Chiu HY, Chiu YM, Chang Liao NF et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agents: a 9-year multicenter cohort study. J Am Acad Dermatol 2021; 85:337–44.
Hoffmann JH, Knoop C, Enk AH et al. Baseline anti-dsDNA concentrations and previous treatments predict response to adalimumab and etanercept: a retrospective investigation of 146 psoriasis patients. J Dermatol Sci 2014; 76:180–5.
Liu Y, Qin G, Meng Z et al. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients. Inflammopharmacology 2019; 27:57–66.
Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 2016; 38:11–27.
ELIXIR Luxembourg. Psoriasis biomarkers. Available at: https://imi-biomap.elixir-luxembourg.org/minerva/index.xhtml?id=psobiomarkers_map (last accessed 26 May 2022).
Dand N, Duckworth M, Baudry D et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol 2019; 143:2120–30.
Talamonti M, Galluzzo M, van den Reek JM et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol 2017; 177:489–96.
Andres-Ejarque R, Ale HB, Grys K et al. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nat Commun 2021; 12:4741.
Wade R, Sharif-Hurst S, Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst Rev 2020; 9:132.
Warren RB, Marsden A, Tomenson B et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol 2019; 180:1069–76.
Savvateeva E, Smoldovskaya O, Feyzkhanova G et al. Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. Crit Rev Clin Lab Sci 2021; 58:17–28.
Curtis JR, Xie F, Crowson CS et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. Arthritis Res Ther 2020; 22:282.
Correa da Rosa J, Kim J, Tian S et al. Shrinking the psoriasis assessment gap: early gene-expression profiling accurately predicts response to long-term treatment. J Invest Dermatol 2017; 137:305–12.
Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. Sensors (Basel) 2012; 12:8966–86.
Muñoz-Aceituno E, Martos-Cabrera L, Ovejero-Benito MC et al. Pharmacogenetics update on biologic therapy in psoriasis. Medicina (Kaunas) 2020; 56:719.
Burlando M, Russo R, Clapasson A et al. The HLA-Cw6 dilemma: is it really an outcome predictor in psoriasis patients under biologic therapy? A monocentric retrospective analysis. J Clin Med 2020; 9:3140.
Chiu HY, Wang TS, Chan CC et al. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol 2014; 171:1181–8.
Costanzo A, Bianchi L, Flori ML et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179:1072–80.
Svedbom A, Nikamo P, Stahle M. Interaction between smoking and HLA-C*06:02 on the response to ustekinumab in psoriasis. J nvest Dermatol 2020; 140:1653–6.
Talamonti M, Botti E, Galluzzo M et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013; 169:458–63.
van den Reek J, Coenen MJH, van de L’Isle Arias M et al. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. Br J Dermatol 2017; 176:1288–96.
Zorlu O, Bülbül Başkan E, Yazici S et al. Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatolog Treat 2022; 33:437–42.
Ovejero-Benito MC, Prieto-Perez R, Llamas-Velasco M et al. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics 2018; 19:7–16.
Prieto-Perez R, Llamas-Velasco M, Cabaleiro T et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics 2017; 18:157–64.
Prieto-Perez R, Solano-Lopez G, Cabaleiro T et al. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J 2018; 18:70–5.
Batalla A, Coto E, Gomez J et al. IL17RA gene variants and anti-TNF response among psoriasis patients. Pharmacogenomics J 2018; 18:76–80.
Loft ND, Skov L, Iversen L et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J 2018; 18:494–500.
Coto-Segura P, Gonzalez-Fernandez D, Batalla A et al. Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis. Br J Dermatol 2016; 175:134–41.
Coto-Segura P, Batalla A, Gonzalez-Fernandez D et al. CDKAL1 gene variants affect the anti-TNF response among psoriasis patients. Int Immunopharmacol 2015; 29:947–9.
